Citation Impact 2023
Journal Impact Factor: 6.1
5-year Journal Impact Factor: 7.1
Source Normalized Impact per Paper (SNIP): 1.865
SCImago Journal Rank (SJR): 2.578
Speed 2024
Submission to first editorial decision (median days): 12
Submission to acceptance (median days): 145
Usage 2024
Downloads: 2,971,481
Altmetric mentions: 1,091
Articles
Page 111 of 112
-
Citation: Breast Cancer Research 1999 2:66640
-
Progostic LOH markers for breast cancer
Citation: Breast Cancer Research 1999 2:66637 -
BRCA1 and Rb?
Citation: Breast Cancer Research 1999 2:66636 -
Telomerase inhibition reduces cell growth
Citation: Breast Cancer Research 1999 2:66634 -
Mutual interaction between breast epithelial and fibroblast cells
Citation: Breast Cancer Research 1999 2:66633 -
Organochlorine pesticides: an effect on estrogen activity?
Citation: Breast Cancer Research 1999 2:66632 -
Liposomal doxorubicin in metastatic breast cancer
Citation: Breast Cancer Research 1999 2:66629 -
Adenoviral topoisomerase II αgene transfer increases sensitivity of resistant cancer cells
Citation: Breast Cancer Research 1999 1:66618 -
High dose chemotherapy in inflammatory breast cancer
Citation: Breast Cancer Research 1999 1:66617 -
Extracellular matrix modulates mammary gland growth factor signalling
Citation: Breast Cancer Research 1999 1:66612 -
Use of cDNA microarrays in breast cancer
Citation: Breast Cancer Research 1999 1:66611 -
The effects of HER2 monoclonal antibody in women with HER2-overexpressing metastatic breast cancer
Citation: Breast Cancer Research 1999 1:66610 -
Idoxifene antagonises E2-dependent breast cancer xenograft growth through apoptosis
Citation: Breast Cancer Research 1999 1:66609 -
Visibility of cancer on earlier mammograms in the Finnish breast screening programme
Citation: Breast Cancer Research 1999 1:66608 -
Role of the mitotic checkpoint in transformation of Brca2 null cells
Citation: Breast Cancer Research 1999 1:66606 -
Stromelysin-1 promotes mammary carcinogenesis
Citation: Breast Cancer Research 1999 1:66605 -
Autologous stem-cell transplantation of hematopoietic cells containing the MDR1 cDNA
Citation: Breast Cancer Research 1999 1:66604 -
ZACdownregulation in breast tumors
Citation: Breast Cancer Research 1999 1:66603 -
Liposome-plasmid complexes encoding angiostatin and endostatin inhibit breast cancer in nude mice
Citation: Breast Cancer Research 1999 1:66602 -
Pathologic findings from the NSABP B-17 protocol: 8 year update
Citation: Breast Cancer Research 1999 1:66601 -
BRCA1-associated DNA repair
Citation: Breast Cancer Research 1999 1:66598 -
Interval cancers in the Scottish screening programme
Citation: Breast Cancer Research 1999 1:66596 -
MMTV-c-erbB-2 and MMTV-TGF alpha transgenic rats
Citation: Breast Cancer Research 1999 1:66595 -
Micrometastases and survival in women with primary breast cancer
Citation: Breast Cancer Research 1999 1:66594 -
ER in normal and pre-cancerous breast
Citation: Breast Cancer Research 1999 1:66593 -
Genetic prodrug activation in erbB-2 overexpressing breast cancer
Citation: Breast Cancer Research 1999 1:66591 -
Whole-genome scan for common breast cancer?
Citation: Breast Cancer Research 1999 1:66590 -
Raloxifene and breast cancer risk
Citation: Breast Cancer Research 1999 1:66588 -
Impact of mammographic screening in New South Wales
Citation: Breast Cancer Research 1999 1:66587 -
Edinburgh breast screening trial, 14 year follow up
Citation: Breast Cancer Research 1999 1:66586 -
Tamoxifen treatment for DCIS - NSABP B-24 trial
Citation: Breast Cancer Research 1999 1:66585 -
Report from 16 year UK breast screening trial
Citation: Breast Cancer Research 1999 1:66584 -
Mammary gland cell proliferation and steroid receptor expression
Citation: Breast Cancer Research 1999 1:66582 -
VEGFR-3 and VEGF-C in angiogenesis
Citation: Breast Cancer Research 1999 1:66578 -
Cyclin D1expression during rat mammary tumor development and its potential role in the resistance of the Copenhagen rat
Resistance to mammary tumorigenesis in Copenhagen rats isassociated with loss of early preneoplastic lesions known as intraductalproliferations. The cause of this disappearance, however, is unknown.
Citation: Breast Cancer Research 1999 1:88 -
Glutathione S-transferase M1 null genotype: lack of association with tumour characteristics and survival in advanced breast cancer
Glutathione S-transferase (GST)M1, a member of the μ class GST gene family, has been shown to be polymorphic because of a partial gene deletion. This results in a failure to express the GSTM1 gene in 50-60% of in...
Citation: Breast Cancer Research 1999 1:81 -
The Million Women Study: design and characteristics of the study population
To describe the design of the Million Women Study and the characteristics of the study population.
Citation: Breast Cancer Research 1999 1:73 -
Late-breaking breast cancer research: from genomics to new drugs
Citation: Breast Cancer Research 1999 1:54 -
Second International Workshop on the function of BRCA1 and BRCA2, Cambridge, UK, 9 to 10 September 1999
Citation: Breast Cancer Research 1999 1:52 -
The pathology of familial breast cancer: The pathology of familial breast cancer How do the functions of BRCA1 and BRCA2 relate to breast tumour pathology?
Women with mutations in the breast cancer susceptibility genes, BRCA1 and BRCA2, have an increased risk of developing breast cancer. Both BRCA1 and BRCA2 are thought to be tumour suppressor genes since the wild t...
Citation: Breast Cancer Research 1999 1:41 -
The pathology of familial breast cancer: Immunohistochemistry and molecular analysis
Extensive studies of BRCA1- and BRCA2-associated breast tumours have been carried out in the few years since the identification of these familial breast cancer predisposing genes. The morphological studies sugges...
Citation: Breast Cancer Research 1999 1:36 -
The pathology of familial breast cancer: Morphological aspects
A small proportion of breast cancers are due to a heritable predisposition. Recently, two predisposition genes, BRCA1 and BRCA2, have been identified and cloned. The morphological features of tumours from patient...
Citation: Breast Cancer Research 1999 1:31 -
The pathology of familial breast cancer: The pre-BRCA1/BRCA2 era - historical perspectives
A proportion of breast carcinomas develop as a result of a genetic predispostion to the disease. Prior to cloning of the BRCA1 and BRCA2 genes a limited number of studies were carried out to identify specific his...
Citation: Breast Cancer Research 1999 1:27 -
Opinion: why the variation in breast cancer survival in Europe?
Citation: Breast Cancer Research 1999 1:22 -
Endogenous hormones and the aetiology of breast cancer
Citation: Breast Cancer Research 1999 1:18 -
How many more breast cancer predisposition genes are there?
Citation: Breast Cancer Research 1999 1:14 -
Epithelial stem cells in the mammary gland: casting light into dark corners
The epithelial structures of the human breast or the mouse mammary gland are derived from a relatively small number of multipotent, tissue-specific stem cells, of which we are surprisingly ignorant. We do not ...
Citation: Breast Cancer Research 1999 1:11 -
Killing the umpire: cooperative defects in mitotic checkpoint and BRCA2 genes on the road to transformation
Recent findings from mouse models of BRCA2 genetic lesions have provided intriguing insights and important questions concerning modes of tumor development in familial breast and ovarian cancers. Fibroblasts fr...
Citation: Breast Cancer Research 1999 1:8 -
Bringing estrogen receptors under control
Citation: Breast Cancer Research 1999 1:5 -
Do we now have a relevant animal model for breast cancer?
Citation: Breast Cancer Research 1999 1:2